Lesi sihloko sizokusiza ukuthi ukhethe ukuthi iyiphi ofaneleka kakhulu kuyo ngokuphendula imibuzo elandelayo:
1.Uyini umehluko phakathi kwe-tirzepatide ne-retatrutide?
2.Iziphi izinzuzo ze-tirzepatide?
3.Iziphi izinzuzo ze-retatrutide?
4.Ukuqhathanisa Izinzuzo ze-Retatrutide ne-Tirzepatide
Uyini umehluko phakathi kwe-tirzepatide ne-retatrutide?
Umehluko omkhulu phakathi kwe-tirzepatide ne-retatrutide usesakhiweni sabo.I-Tirzepatide iyinhlanganisela yezingxenye ezintathu ezisebenzayo - i-liraglutide, i-glucagon-like peptide-1 agonist (GLP-1);i-analogue ye-oxyntomodulin;kanye ne-analogue ye-GLP-2.I-Retarutide, ngakolunye uhlangothi, yakhiwa isakhi esisodwa esisebenzayo - i-exenatide, enye i-GLP-1 evezwe ngokweqile kuma-pancreas.Yomibili le mithi isetshenziselwa ukuphatha isifo sikashukela sohlobo 2 ngokwandisa ukukhiqizwa kwe-insulin nokwehlisa amazinga kashukela egazini.Kodwa-ke, i-retarutide nayo iboniswe ukunciphisa isifiso sokudla ngokuphumelelayo kune-tirzepatide iyodwa ngenxa yomphumela wayo kuma-hormone ahilelekile endlala nokusutha.Kanjalo, ingasetshenziswa njengengxenye yendlela edidiyelwe yokulawulwa kwesisindo kubantu abanesifo sikashukela abakhuluphele noma abakhuluphele.
Yiziphi izinzuzo ze-tirzepatide?
①Ukulawulwa kwe-glycemic okuthuthukisiwe namazinga e-A1C, okuholela empilweni engcono kakhulu
I-Tirzepatide, i-glucagon-like peptide 1 receptor agonist kanye ne-GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonist, iyindlela entsha yokwelapha yohlobo 2 lwesifo sikashukela.Kutholakale ukuthi kusebenza kangcono kune-retatrutide ekuthuthukiseni ukulawulwa kwe-glycemic namazinga e-A1C.Ezivivinyweni zomtholampilo, i-tirzepatide ihlotshaniswa nokunciphisa okukhulu kwamazinga e-A1C kumaviki angu-12 uma kuqhathaniswa ne-retatrutide (-2.3% vs -1.8%), okuholela emiphumeleni engcono yezempilo jikelele yeziguli.
②Ingozi encishisiwe yezehlakalo zenhliziyo nemithambo yegazi njengokuhlasela kwenhliziyo nesifo sohlangothi
I-Tirzepatide inikeza uhla lwezinzuzo ezingaba khona kubantu abasengcupheni yezehlakalo zenhliziyo nemithambo yegazi njengokuhlasela kwenhliziyo nesifo sohlangothi.Ucwaningo lwango-2019 olushicilelwe kumagazini i-Lancet luthole ukuthi abantu abathatha i-tirzepatide babenengozi ephansi kakhulu yezehlakalo ezimbi zenhliziyo nemithambo yegazi (MACE) uma kuqhathaniswa nalabo abathatha i-retatrutide.Lokhu kufaka phakathi ukuncipha kwe-MACE okungama-35% uma kuqhathaniswa ne-retatrutide, engabonisanga umehluko omkhulu ekusebenzeni ezingozini zenhliziyo nemithambo yegazi.Phakathi nocwaningo, abacwaningi baqaphele ukuthi iziguli ezithatha i-tirzepatide zithole amazinga aphansi e-coronary artery disease, i-myocardial infarction, ukuhluleka kwenhliziyo ehlangene kanye nesifo sohlangothi kunalabo abaseqenjini le-retatrutide.Ukwengeza, ababambiqhaza abathathe i-tirzepatide baphinde babika amazinga athuthukisiwe okulawula ushukela wegazi kanye nokuzuza okuncane kwesisindo uma kuqhathaniswa nalabo abathatha i-retatrutide.Okokugcina, kufanele kuqashelwe ukuthi abantu abathatha i-tirzepatide abazange bavikeleke kuphela ku-MACE kodwa futhi babe nokuncipha kwamazinga e-HbA1c (umaka wokulimala kwesifo sikashukela isikhathi eside) kanye namaphesenti wamafutha omzimba uma eqhathaniswa namazinga okuqala.Ekugcineni, le miphumela ikhomba amandla e-tirzepatide ukunciphisa imicimbi yenhliziyo nemithambo yegazi ehambisana nesifo sikashukela sohlobo 2 futhi inikeze izinzuzo ezengeziwe ezihlobene nokwakheka komzimba.
Isisindo somzimba esiphansi uma siqhathaniswa ne-retatrutide, engasiza ekunciphiseni ingozi yezifo ezihlobene nokukhuluphala
I-Tirzepatide inezinzuzo eziningana uma iqhathaniswa ne-retatrutide, ikakhulukazi uma kuziwa esisindweni somzimba.Ucwaningo luye lwathola ukuthi i-tirzepatide ingaholela ekunciphiseni okuphawulekayo kwesisindo somzimba kune-retatrutide esikhathini eside.Lokhu kungabangelwa ikhono layo lokuvuselela umsebenzi wama-GLP-1 receptor nokukhuthaza ukusutha.Ngaphezu kwalokho, i-tirzepatide itholakale inciphisa amafutha esiswini kangcono kune-retatrutide, engasiza ekunciphiseni ingozi yesifo sikashukela, izifo zenhliziyo, nezinye izifo ezihlobene nokukhuluphala.Ngaphezu kwalokho, i-tirzepatide ikhonjiswe ukunciphisa amazinga kashukela egazi ngempumelelo kune-retatrutide.Le miphumela ihlanganisiwe ingathuthukisa imiphumela yezempilo iyonke ehlobene nokukhuluphala kanye nokungasebenzi kahle kwe-metabolic.
③Ukwenyuka kwamazinga wamandla ngenxa yokwenziwa ngcono kwe-glucose metabolism
Enye yezinzuzo ezibalulekile zokuthatha i-tirzepatide amandla ayo okukhulisa amazinga wamandla ngenxa yokwenziwa ngcono kwe-glucose metabolism.Lokhu kungenxa yokuthi ama-agonists e-GLP1 receptor athanda umsebenzi we-tirzepatide ngokuvuselela ukukhishwa kwe-insulin ukuphendula amazinga aphezulu kashukela egazini.Ngokwandisa ukukhiqizwa kwe-insulin nokuthuthukisa imetabolism ye-glucose, umzimba ungasebenzisa i-glucose eyengeziwe ukuze uthole uphethiloli futhi lokhu kungaholela ekwandeni kwamazinga wamandla.Ngaphezu kwalokho, ama-agonists e-GLP1 receptor anganciphisa isifiso sokudla, okuholela ekunciphiseni izifiso zokudla kanye nokuphathwa kwesisindo okuthuthukisiwe.
Yiziphi izinzuzo ze-retatrutide?
I-Retatrutideumuthi ojova isikhathi eside osetshenziswa ukwelapha isifo sikashukela sohlobo 2.Igunyazwe i-US Food and Drug Administration (FDA) ngale njongo.Izinzuzo ze-retatrutide ziningi, okwenza kube inketho ekhangayo phakathi kweminye imithi yesifo sikashukela.
Okokuqala, i-retatrutide isebenza ngokushesha uma isijovwe futhi imiphumela yayo ingazwakala phakathi namahora angama-24 okuphathwa.Lokhu kuyenza isebenze ngokushesha kakhulu kuneminye imijovo esebenza isikhathi eside njenge-tirzepatide, engathatha amasonto ambalwa ngaphambi kokuba noma yimiphi imiphumela ebonakalayo ibonakale kumazinga kashukela egazini.
Ngaphezu kwalokho, ucwaningo luye lwabonisa ukuthi i-retatrutide iyasebenza ekwehliseni amazinga e-A1C kubantu abanesifo sikashukela sohlobo 2 lapho kuthathwa kanye nezinguquko zokudla nokuzivocavoca.Izivivinyo zemitholampilo ziphinde zabonisa ukuthi i-retatrutide isiza ukwehlisa amazinga eglucose azilayo kanye nokulawulwa kwe-glycemic kukonke kubasebenzisi uma kuqhathaniswa ne-placebo.Kwezinye izimo, abantu abangazange bathole nzuzo emithini yesifo sikashukela somlomo baye baba nemiphumela ephumelelayo ngokwelashwa kwe-retatrutide.
Okokugcina, enye yezinzuzo ezinkulu ze-retatrutide yinqubo yayo yokuphatha elula;kudinga umjovo owodwa nje ngesonto esikhundleni semijovo eminingi yansuku zonke njengezinye izindlela eziningi zokwelapha isifo sikashukela.Lokhu kungenza ukunakekela isifo sikashukela kube lula kakhulu futhi kusize ukuthuthukisa ukubambelela kwesiguli ohlelweni lokwelapha ngokuhamba kwesikhathi.
Ukuqhathanisa Izinzuzo ze-Retatrutide ne-Tirzepatide
Uma kuziwa ekusebenzeni kahle, i-retatrutide ikhonjiswe ukuthi yehlisa amazinga e-HbA1c ngo-1.9-2.4%, uma kuqhathaniswa ne-Tirzepatide eyehlisa amazinga e-HbA1c ngo-1.5-2%.Yomibili le mithi inemiphumela emibi efanayo, njengokucanuzela kwenhliziyo nekhanda.Nokho, abanye abantu bangathola ukuthi baba nemiphumela engemihle embalwa nge-Retatrutide kune-Tirzepatide ngenxa yezidingo zayo eziphansi zomthamo.
Mayelana nokuphepha, i-retarutide ngokuvamile ibekezelelwa kahle uma isetshenziswa ngemithamo enconyiwe futhi ayiwandisi ingozi ye-hypoglycemia noma ibangele ukukhuluphala njengoba kwenza ezinye izindlela zokwelapha isifo sikashukela.Ngakolunye uhlangothi, i-Tirzepatide ithwala ingozi enkulu yokusabela kwendawo yomjovo ngenxa yobukhulu bayo obukhulu.Ukwengeza, uma kuthathwa imithamo eyeqile kungadala i-hypoglycemia enzima kanye nesisindo somzimba.
Kafushane, kokubili i-retarutide ne-tirzepatide yizinketho ezisebenzayo zokulawula uhlobo lwesifo sikashukela sohlobo 2 kodwa eyodwa ingase ifaneleke kakhulu ezigulini ezithile kuye ngezidingo zazo ngazinye.I-Retarutide inikeza ukusebenza kahle okuhle ngemiphumela engemihle embalwa kuyilapho futhi iphephile ngemithamo enconyiwe;nokho, i-Tirzepatide inganikeza ukuncipha okukhulu kumazinga e-HbA1c kodwa futhi ingathwala ingozi ephezulu yemiphumela emibi kakhulu uma ingasetshenziswa kahle.Ekugcineni, kubalulekile ukubonisana nodokotela wakho ukuze unqume ukuthi iyiphi inketho yokwelashwa ekulungele ngokusekelwe ezimweni zakho ezithile kanye nemigomo yezempilo.
Qala ukwelashwa kwakho kwe-tirzepatide kanye ne-semaglutide e-LianFu
Isikhathi sokuthumela: Mar-18-2024